+ Watch PTIE
on My Watchlist
A biopharmaceutical company that develops novel drugs for pain management and oncology.
Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat metastatic melanoma. The Company's lead drug candidate is REMOXY, which is a painkiller. It has a collaboration agreement and a license agreement with King Pharmaceuticals, Inc. (King) to develop and commercialize REMOXY and other opioid painkillers. I am not excited about this company. Right now the company is not profitable. One year EPS growth is encouraging at 412.50%. The Return on Equity is a pitiful -3.23. The positive consideration is that there is always interest in effective pain medicines. Stock has been on a steady upward progression over the last year. However, this stock may be overbought, and I expect the stock price will begin to decline in price a bit. I do believe after a short correction this stock will outperform the market.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions